PMID- 34113073
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 15
DP  - 2021
TI  - The Effect of Dietary Antioxidant Supplementation in Patients with Glaucoma.
PG  - 2293-2300
LID - 10.2147/OPTH.S314288 [doi]
AB  - PURPOSE: Oxidative stress may be a risk factor for glaucoma, and many previous 
      reports have suggested that antioxidants could be a promising treatment. Here, we 
      investigated the effects of a novel supplement containing three food-derived 
      antioxidants (hesperidin, crocetin, and Tamarindus indica) on markers of 
      oxidative stress in patients with glaucoma. PATIENTS AND METHODS: This study had 
      a prospective, single arm design. Thirty Japanese glaucoma patients were 
      recruited and given 4 tablets with ample water twice a day for 8 weeks. The 
      treatment was stopped, and the subjects were followed for an additional 8 weeks. 
      We measured biological antioxidant potential (BAP) with a free radical analyzer. 
      We also measured urinary 8-hydroxy-2'-deoxyguanosine (8-OHdG; a marker of 
      oxidative DNA damage). Clinical laboratory data were measured in venous blood 
      samples. Clinical parameters were also recorded. Comparisons used a one-way 
      analysis of variance (ANOVA) followed by Dunnett's test. RESULTS: The 8-OHdG 
      level was not reduced. We also divided the patients into groups with high or low 
      oxidative stress. In patients with relatively high oxidative stress, the 8-OHdG 
      level was significantly reduced at weeks 4, 8, 12, and 16 (P < 0.001, P < 0.01, P 
      < 0.01, P < 0.01), and BAP was significantly elevated at weeks 8 and 12 (P = 
      0.03, P = 0.04). In patients with relatively low oxidative stress, the 8-OHdG 
      level was not significantly reduced during supplement intake but was 
      significantly elevated at weeks 12 and 16 (P =0.03, P = 0.04), while BAP was not 
      significantly elevated. CONCLUSION: An 8-week oral course of antioxidant 
      supplementation was effective in patients with a high oxidative stress level. 
      Dietary supplementation could hold promise in the treatment of systemic oxidative 
      stress-related diseases.
CI  - (c) 2021 Himori et al.
FAU - Himori, Noriko
AU  - Himori N
AUID- ORCID: 0000-0001-8307-0458
AD  - Department of Ophthalmology, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
FAU - Inoue Yanagimachi, Maki
AU  - Inoue Yanagimachi M
AD  - Department of Ophthalmology, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
FAU - Omodaka, Kazuko
AU  - Omodaka K
AD  - Department of Ophthalmology, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
AD  - Department of Ophthalmic Imaging and Information Analytics, Tohoku University 
      Graduate School of Medicine, Sendai, Japan.
FAU - Shiga, Yukihiro
AU  - Shiga Y
AD  - Department of Ophthalmology, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
FAU - Tsuda, Satoru
AU  - Tsuda S
AD  - Department of Ophthalmology, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
FAU - Kunikata, Hiroshi
AU  - Kunikata H
AD  - Department of Ophthalmology, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
AD  - Department of Retinal Disease Control, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
FAU - Nakazawa, Toru
AU  - Nakazawa T
AD  - Department of Ophthalmology, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
AD  - Department of Ophthalmic Imaging and Information Analytics, Tohoku University 
      Graduate School of Medicine, Sendai, Japan.
AD  - Department of Retinal Disease Control, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
AD  - Department of Advanced Ophthalmic Medicine, Tohoku University Graduate School of 
      Medicine, Sendai, Japan.
LA  - eng
PT  - Case Reports
PT  - Clinical Trial
DEP - 20210602
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC8183457
OTO - NOTNLM
OT  - 8-OHdG
OT  - glaucoma
OT  - oxidative stress
OT  - supplement
COIS- Professor Toru Nakazawa reports grants from Wakamoto Pharmaceutical Co., 
      Ltd. during the conduct of this study;  grants and personal fees from Santen 
      Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., and Topcon Corporation, 
      outside the submitted work;  grants from Nidek Co., Ltd.  This research was 
      supported by Wakamoto Pharmaceutical Co., Ltd. The authors report no other 
      conflicts of interest in this work.
EDAT- 2021/06/12 06:00
MHDA- 2021/06/12 06:01
PMCR- 2021/06/02
CRDT- 2021/06/11 06:40
PHST- 2021/04/04 00:00 [received]
PHST- 2021/05/18 00:00 [accepted]
PHST- 2021/06/11 06:40 [entrez]
PHST- 2021/06/12 06:00 [pubmed]
PHST- 2021/06/12 06:01 [medline]
PHST- 2021/06/02 00:00 [pmc-release]
AID - 314288 [pii]
AID - 10.2147/OPTH.S314288 [doi]
PST - epublish
SO  - Clin Ophthalmol. 2021 Jun 2;15:2293-2300. doi: 10.2147/OPTH.S314288. eCollection 
      2021.